CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
TILT Biotherapeutics is developing innovative gene therapies for cancer, focusing on TILT-123, an oncolytic adenovirus designed to activate the immune system against tumors. This therapy aims to treat patients with difficult-to-treat cancers by enhancing immune responses and improving treatment efficacy.
TILT Biotherapeutics is a clinical-stage biotechnology company developing novel gene therapies for cancer. TILTs lead asset, TILT-123, is an oncolytic adenovirus armed with two human cytokines:
TNF alpha and IL-2. TILT-123 is now in several Phase 1 clinical trials in Europe, the U.S. and China.
The asset has been tailored to immunologically heat up cold tumors.
Multiple antitumor mechanisms are activated: direct immunogenic killing of cancer cells while sparing healthy cells, release of tumor ep…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
